IP Library Granted Patent US 8,257,372
Granted Patent B2
US 8,257,372 · App. 12/648,458 · Granted Sep 4, 2012

System for providing fluid flow to nerve tissues

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,257,372
App. No.
12/648,458
Granted
Sep 4, 2012
Kind
B2
Abstract

Provided is an apparatus that includes a nerve conduit, a manifold and a support structure for providing a reduced pressure. Also provided is a system that includes a source of reduced pressure, a nerve conduit, a manifold, a support structure and a conduit for providing fluid communication between the manifold support and the source of reduced pressure. Additionally provided is a method that includes implanting the above nerve conduit, manifold and support structure at a site of damaged nerve tissue and applying a reduced pressure to the manifold thereby stimulating repair or regrowth of nerve tissue.

Claims (31)

1. An apparatus for providing reduced pressure from a reduced-pressure source to a defect at a tissue site of a nerve, the apparatus comprising:

a nerve conduit having a generally tubular shape having walls including an exterior wall and a luminal wall surrounding the tissue site to contain fluids within a luminal space between the tissue site and the luminal wall and prevent bodily fluids from entering the luminal space;

a manifold having a generally cylindrical body having surfaces including a side wall surface and two end wall surfaces, a first end wall surface of the two end wall surfaces for receiving reduced pressure, a fluid contact surface including a first portion of the surfaces of the cylindrical body other than the first end wall surface for fluid communication with the luminal space, and a support surface including a second portion of the surface of the cylindrical body other than the first end wall surface and the fluid contact surface, wherein the manifold comprises a porous material having a plurality of flow channels to deliver reduced pressure to the luminal space for providing reduced pressure therapy to the tissue site; and

a support structure having a generally tubular shape for enclosing the support surface, a first end portion for coupling the first end wall surface to the reduced-pressure source, and a second end portion for coupling the manifold to the nerve conduit in a generally radial direction with respect to the luminal wall.

2. The apparatus of claim 1 , wherein the fluid contact surface comprises a second end wall surface of the two end wall surfaces positioned adjacent the luminal wall to fluidly communicate with the luminal space.

3. The apparatus of claim 2 , wherein the nerve conduit comprises a material generally impermeable to fluids from tissue surrounding the nerve conduit.

4. The apparatus of claim 1 , wherein the nerve conduit is porous and the fluid contact surface comprises a second end wall surface of the two end wall surfaces positioned adjacent the exterior wall of the nerve conduit to fluidly communicate with the luminal space through the walls of the nerve conduit.

5. The apparatus of claim 4 , wherein the nerve conduit comprises a material generally impermeable to fluids from tissue surrounding the nerve conduit.

6. The apparatus of claim 1 , wherein the defect is a severed, partially severed, pinched, or degenerated nerve.

7. The apparatus of claim 1 , wherein the second end portion of the support structure comprises a flange.

8. The apparatus of claim 1 , wherein the second end portion of the support structure provides a detachable coupling of the manifold to the nerve conduit.

9. The apparatus of claim 1 , wherein the second end portion of the support structure comprises an adhesive for coupling the manifold and the nerve conduit.

10. The apparatus of claim 1 , wherein the manifold comprises a porous structure wherein the pore size is sufficiently small to exclude cells from entering the manifold.

11. The apparatus of claim 1 , wherein the nerve conduit comprises pores that are sufficiently small to exclude the entry of cells into the luminal space.

12. The apparatus of claim 11 , wherein the pores have an interior diameter of between about 5 μm and 50 μm.

13. The apparatus of claim 1 , wherein the manifold is positioned on a distal side of the nerve conduit relative to the tissue site.

14. The apparatus of claim 1 , wherein the manifold provides reduced pressure preferentially to a distal side of the nerve relative to the tissue site.

15. The apparatus of claim 1 , wherein the manifold or nerve conduit is composed of a bioinert material.

16. The apparatus of claim 1 , wherein the manifold or nerve conduit is composed of a bioabsorbable material.

17. The apparatus of claim 1 , wherein the luminal space of the nerve conduit comprises a scaffold that facilitates tissue growth or regrowth.

18. The apparatus of claim 17 , wherein the scaffold is formed from a foam or gel material.

19. The apparatus of claim 17 , wherein the scaffold comprises biological material selected from fibrin or collagen.

20. The apparatus of claim 19 , wherein the scaffold material comprises a bioactive agent.

21. The apparatus of claim 20 , wherein the bioactive agent is at least one of an antibiotic, an antibody and a growth factor.

22. The apparatus of claim 21 , wherein the bioactive agent is a growth hormone (GH), a bone morphogenetic protein (BMP), transforming growth factor-a (TGF-α), a TGF-β, a fibroblast growth factor (FGF), granulocyte-colony stimulating factor (G-CSF), granulocyte/macrophage-colony stimulating factor (GM-CSF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor/scatter factor (HGF/SF), an interleukin, tumor necrosis factor-α (TNF-α) or nerve growth factor (NGF).

23. The apparatus of claim 1 , wherein the nerve conduit comprises a slice along its length that forms an opening whereby the nerve conduit is implantable around the tissue site and sealable with one or more closure elements.

24. A system for providing reduced pressure to a defect at a tissue site of a nerve, the system comprising:

a pressure source for supplying the reduced pressure;

a nerve conduit having a generally tubular shape having walls including an exterior wall and a luminal wall surrounding the tissue site to contain fluids within a luminal space between the tissue site and the luminal wall and prevent bodily fluids from entering the luminal space;

a manifold having a generally cylindrical body having surfaces including a side wall surface and two end wall surfaces, a first end wall surface of the two end wall surfaces in fluid communication with the pressure source, a fluid contact surface including a first portion of the surfaces of the cylindrical body other than the first end wall surface for fluid communication with the luminal space, and a support surface including a second portion of the surface of the cylindrical body other than the first end wall surface and the fluid contact surface, wherein the manifold comprises a porous material having a plurality of flow channels to deliver reduced pressure to the luminal space for providing reduced pressure therapy to the tissue site; and

a support structure having a generally tubular shape for enclosing the support surface, a first end portion for coupling the first end wall surface to the reduced-pressure source, and a second end portion for coupling the manifold to the nerve conduit in a generally radial direction with respect to the luminal wall.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: 3M INNOVATIVE PROPERTIES COMPANY
To: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY
Reel/Frame 066443/0513 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION LISTED ON SCHEDULE OF IP RIGHTS ATTACHED TO ASSIGNMENT AT LINES 55: 71; 89; 116-129; AND 131 NEED TO BE DELETED PREVIOUSLY RECORDED AT REEL: 064788 FRAME: 0823. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 13, 2023
From: KCI LICENSING, INC.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 064886/0479 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2023
From: KCI LICENSING, INC.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 064788/0823 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Nov 7, 2019
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: KCI USA, INC.; KCI LICENSING, INC.
Reel/Frame 050966/0547 →
RELEASE OF SECURITY INTEREST REEL/FRAME 040098/0268 Recorded Feb 8, 2017
From: WILMINGTON TRUST
To: KCI USA, INC.
Reel/Frame 041666/0320 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →